UTILIZATION OF NK CELLS IN PREVENTION OF RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION - CLINICAL STUDY PHASE IB/II
Abstract
Relapse is the most common cause of death in patients after allogeneic hematopoietic cell transplantation (AlloHSCT). Patients with a high-risk disease according to the disease risk index (DRI) or patients with measurable residual disease after AlloHSCT have a high risk of disease relapse with limited therapeutic options.
Adoptive immunotherapy using ex vivo expanded and activated NK cells represents a potential treatment modality for relapse prevention.